RxDoctor Payments Data

Jennifer Alyono, MD

Otology & Neurotology · Stanford, CANPI 1790075026

Payments from drug & device makers

What this record shows

Stryker accounts for 67.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $1,700 and has fallen 75.8% since, to $412 in 2025.

$2,539in general payments, 2019–2025

Across 28 payments — averaging $90.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Cochlear Americas$431
  • Medtronic$192
  • Johnson & Johnson$145
  • Smith+Nephew$71
$192,117in research payments, 2019–2025

Across 32 payments — averaging $6003.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cochlear Americas$192K

What the payments were for

  • Travel & lodging$1,32752%
  • Food & beverage$1,21248%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker11$1,700
Cochlear Americas5$431
Medtronic10$192
Johnson & Johnson1$145
Smith+Nephew1$71

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,539 in reported general payments places this provider in the 60th percentile of 43 otology & neurotology providers in California.

See all otology & neurotology providers in California

Medicare billing

Part B allowed, 2024
$99,125
Medicare patients
276
Services billed
492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth21$2,428
Ofloxacin15$660
Cephalexin22$72
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$42

Paid to pharmacies, not to this prescriber.

Other otology & neurotology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →